+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

THU0419Integrated Safety of Ustekinumab in Psoriatic Arthritis: 2 Year Follow-Up from the Psoriatic Arthritis Clinical Development Program



THU0419Integrated Safety of Ustekinumab in Psoriatic Arthritis: 2 Year Follow-Up from the Psoriatic Arthritis Clinical Development Program



Annals of the Rheumatic Diseases 74(Suppl 2): 350.1-350




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 064769886

Download citation: RISBibTeXText

DOI: 10.1136/annrheumdis-2015-eular.2771


Related references

SAT0287Long-Term Safety Of Ustekinumab: 5 Years of Follow-Up from the Psoriasis Clinical Development Program Including Patients with Psoriatic Arthritis. Annals of the Rheumatic Diseases 72(Suppl 3): A680.2-A680, 2013

Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs. Drug Safety 42(6): 751-768, 2019

Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis and Rheumatism 56(8): 2698-2707, 2007

Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Journal of Rheumatology 35(5): 869-876, 2008

Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis and Rheumatism 59(5): 686-691, 2008

Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Annals of the Rheumatic Diseases 73(2): 407-413, 2014

The safety of ustekinumab for the treatment of psoriatic arthritis. Expert Opinion on Drug Safety 16(6): 733-742, 2017

Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. Journal of Rheumatology 43(12): 2120-2130, 2016

SAT0396Efficacy and Safety of Ustekinumab in Patients with Active Psoriatic Arthritis: 2-Year Results from A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study. Annals of the Rheumatic Diseases 73(Suppl 2): 737.2-738, 2014

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382(9894): 780-789, 2013

Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS). Annals of the Rheumatic Diseases 68(4): 497-501, 2009

Development of a disease activity and responder index for psoriatic arthritis--report of the Psoriatic Arthritis Module at OMERACT 11. Journal of Rheumatology 41(4): 782-791, 2014

Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Journal of Rheumatology 45(10): 1389-1396, 2018

Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial. Arthritis Research and Therapy 21(1): 125, 2019

Development and pilot-testing of a new tool to screen psoriasis patients for the presence of psoriatic arthritis: the Simple Psoriatic Arthritis Screening (SiPAS) questionnaire. Journal of the European Academy of Dermatology and Venereology 31(3): E167-E169, 2017